| 1 |
35194103 | CYP2B6 allelic variants and non-genetic factors influence CYP2B6 enzyme function. | 2022 Feb 22 |
1 |
| 2 |
34114066 | Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients. | 2021 Sep |
2 |
| 3 |
31555969 | Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning. | 2020 Jan |
1 |
| 4 |
31773494 | Correction to: Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning. | 2020 Jan |
1 |
| 5 |
27482943 | The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. | 2017 Jan |
1 |
| 6 |
25448283 | Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants. | 2015 Jan 5 |
11 |
| 7 |
25677220 | Cytochrome P450 2B6*5 Increases Relapse after Cyclophosphamide-Containing Conditioning and Autologous Transplantation for Lymphoma. | 2015 May |
4 |
| 8 |
21363914 | Mathematical modeling predicts synergistic antitumor effects of combining a macrophage-based, hypoxia-targeted gene therapy with chemotherapy. | 2011 Apr 15 |
2 |
| 9 |
21543025 | Cytochrome P450 polymorphisms and the response of lupus nephritis to cyclophosphamide therapy. | 2011 May |
3 |
| 10 |
18496131 | Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. | 2008 Jun |
2 |
| 11 |
17082249 | MALDI-TOF mass spectrometry for multiplex genotyping of CYP2B6 single-nucleotide polymorphisms. | 2007 Jan |
2 |
| 12 |
17375983 | Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity. | 2007 |
1 |
| 13 |
17407229 | Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus. | 2007 Apr |
1 |
| 14 |
15746054 | Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. | 2005 Feb 15 |
1 |
| 15 |
15769884 | The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation. | 2005 Jun |
1 |
| 16 |
16116487 | Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. | 2005 |
2 |
| 17 |
16393888 | Metabolism and transport of oxazaphosphorines and the clinical implications. | 2005 |
2 |
| 18 |
14729637 | Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy. | 2004 Jan 1 |
4 |
| 19 |
15248218 | Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. | 2004 Jul |
4 |
| 20 |
12739762 | Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices. | 2003 Apr |
1 |
| 21 |
12052216 | Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. | 2002 |
2 |
| 22 |
12167460 | Effect of cyclophosphamide on gene expression of cytochromes p450 and beta-actin in the HL-60 cell line. | 2002 Aug 9 |
6 |
| 23 |
11377097 | Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology. | 2001 Jun |
1 |
| 24 |
11468938 | A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide. | 2001 Jun |
2 |
| 25 |
11498765 | Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitors. | 2001 Jun |
4 |
| 26 |
11132240 | Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites. | 2000 Nov 24 |
2 |
| 27 |
10348794 | Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. | 1999 Jun |
4 |
| 28 |
9157990 | Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. | 1997 May 15 |
3 |
| 29 |
9241661 | Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. | 1997 Jun |
2 |
| 30 |
8242617 | Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. | 1993 Dec 1 |
3 |
| 31 |
2425812 | Induction of sister chromatid exchanges in human and rat hepatoma cell lines by cyclophosphamide and phosphoramide mustard and the effects of cytochrome P-450 inhibitors. | 1986 Jul 1 |
4 |
| 32 |
6286112 | Effects of cyclophosphamide and polycyclic aromatic hydrocarbons on cell growth and mixed-function oxidase activity in a human colon tumor cell line. | 1982 Sep |
1 |
| 33 |
7387676 | Protection by N-acetylcysteine of cyclophosphamide metabolism - related in vivo depression of mixed function oxygenase activity and in vitro denaturation of cytochrome P-450. | 1980 Apr 14 |
1 |
| 34 |
4432244 | Increased antitumor activity of cyclophosphamide (Endoxan) following pretreatment with inducer of drug-metabolizing enzymes (cytochrome P-450). | 1974 Sep |
2 |